Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Adimab's Search Results Lead to Google Ventures

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Adimab CEO Gerngross wouldn't disclose the amount of Series D money raised, but promised "there will be interactions" between Adimab and parent company Google.

You may also be interested in...



Ablexis' Pharmaceutical Consortium

Ablexis LLC's October 2010 consortium-based alliance with Pfizer Inc. and four other undisclosed "Top 15" drugmakers represents an important new variation in platform-technology deal-making.

Financings Of The Fortnight: IPOs Make A Return In Talecris And Omeros Deals

Money continued to flow to big and small biotechs, including nearly a dozen PIPEs or registered direct offerings.

Financings Of The Fortnight: IPOs Make A Return In Talecris And Omeros Deals

Money continued to flow to big and small biotechs, including nearly a dozen PIPEs or registered direct offerings.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

See All
UsernamePublicRestriction

Register

PS068580

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By